You are here: Industry Insights > Market News > Dr Reddy’s Laboratories launch Abiraterone Acetate Tablets USP in the US

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Dr Reddy’s Laboratories launch Abiraterone Acetate Tablets USP in the US

expresspharmaJune 22, 2020

Tag: Dr Reddy , Abiraterone Acetate Tablets , Zytiga , Prostate Cancer

Favorites

Dr Reddy’s Laboratories announced the launch of Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga (abiraterone acetate) approved by the US Food and Drug Administration (USFDA). The drug is used in the treatment of prostate cancer.

The Zytiga brand and generic market had US sales of approximately $454 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health*.

Dr Reddy’s Abiraterone Acetate is available in 250 mg tablets in bottle count sizes of 120.

Previous:US FDA grants approval to Ultragenyx Pharmaceutical for Crysvita

Next:CDSCO to inspect BDR Pharma’s formulation facility, submit report in seven days

Vetter Wins Best Managed Companies Award 2024

Biotech NewswireMay 30, 2024

Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO), has once again been awarded the Best Managed Companies Award, marking its fifth consecutive win.

ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development

Biotech NewswireMay 30, 2024

New CRO Focused on Cannabis-based Drug Trials Launched

Biotech NewswireMay 23, 2024

Dr Reddy’s Laboratories launch Abiraterone Acetate Tablets USP in the US | Pharmasources.com

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

PharmaSourcesMay 21, 2024

The first patient has been dosed in a clinical trial of the Company's BCL2 inhibitor, ICP-248, in combination with orelabrutinib as a first-line therapy for chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL) in China.

Dr Reddy’s Laboratories launch Abiraterone Acetate Tablets USP in the US

Related News

Vetter Wins Best Managed Companies Award 2024

ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development

New CRO Focused on Cannabis-based Drug Trials Launched

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

You may like